Laserfiche WebLink
DocuSign Envelope ID: 666BF09F-322B-4BBO-BCBO-40579A7ED52C <br />3.1.3 For AI/AN program participants receiving MOUD/MAUD Services, the Contractor's Tribal <br />Liaison or designee, shall coordinate with the program participant's Indian Health Care <br />Provider (IHCP) to ensure the IHCP can participate in treatment and discharge planning, <br />including continuity of care in the nearest IHCP clinically appropriate setting for all AI/AN <br />program participants. <br />3.2. Intake. <br />3.2.1. Continue MOUD and MAUD for individuals who are already taking these medications upon <br />entering the facility. <br />3.2.2. Continue the individual on the same medication at the same dose unless ordered otherwise <br />by the prescriber based on clinical need (documented in the individual's medical record) with <br />the exceptions listed below: <br />3.2.2.1. Injectable long -acting naltrexone may be converted to an equivalent oral dose until <br />just prior to release at which time the injectable form shall be restarted. <br />3.2.2.2. Injectable long -acting buprenorphine may be converted to an equivalent oral dose <br />until just prior to release at which time the injectable form shall be restarted. <br />3.2.2.3. Oral buprenorphine may be converted among the three formulations (film, tablet <br />with naloxone, tablet without naloxone). <br />3.2.2.4. If the individual is not pregnant, methadone may be transitioned to buprenorphine if <br />the jail is not a licensed Opioid Treatment Program (OTP) and the nearest OTP is <br />not within reasonable driving distance from the jail or there is no OTP within <br />reasonable distance of the individual's release residence. <br />3.2.2.5. Though MOUD/MAUD may not be discontinued on a policy or administrative basis <br />because of the presence of other illicit or controlled substances, administration of <br />the community -based MOUD or MAUD may be adjusted if clinically necessary due <br />to pharmacologic risks of drug -drug interaction. <br />3.2.3. Screen all newly admitted individuals for risk of acute withdrawal from opioids and alcohol <br />upon intake. <br />3.2.4. Screen for OUD and AUD without physical dependence (i.e. without a risk of acute <br />withdrawal) after intake, as long as the delay does not impair the ability to begin treatment <br />prior to release. <br />3.2.5. Offer initiation of MOUD treatment to individuals who are physically dependent on opioids. <br />3.2.6. Educate individuals on treatment choices and the process for continuation of access to <br />MOUD, during incarceration, and upon release. <br />3.2.7. Make available and offer treatment using some formulation of methadone, buprenorphine, and <br />naltrexone based on a mutually agreed -upon plan between the prescriber and the individual, <br />with the following exceptions or caveats: <br />3.2.7.1. The jail may decline to offer methadone if the jail is not a licensed OTP and the <br />nearest OTP is not within reasonable driving distance from the jail or there is no <br />OTP within reasonable distance of the individual's release residence. <br />Washington State Page 4 of 10 MOUD in Jails Services <br />Health Care Authority HCA Contract No. K5885-3 <br />Schedule A-3 <br />